Cover Image
市場調查報告書

全球類鴉片物質誘發性便秘 (OIC) 治療藥市場預測

GLOBAL OPIOID INDUCED CONSTIPATION DRUG MARKET FORECAST 2017-2025

出版商 Inkwood Research 商品編碼 535789
出版日期 內容資訊 英文 125 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球類鴉片物質誘發性便秘 (OIC) 治療藥市場預測 GLOBAL OPIOID INDUCED CONSTIPATION DRUG MARKET FORECAST 2017-2025
出版日期: 2017年08月01日 內容資訊: 英文 125 Pages
簡介

本報告提供全球類鴉片物質誘發性便秘 (OIC) 治療藥市場相關調查分析,提供市場概要,各市場區隔的市場分析,各地區分析,競爭分析等系統性資訊。

第1章 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場概要

  • 市場定義
  • 主要市場考察
  • 具吸引力的投資方案
  • OIC治療藥製造商定位
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 市場課題

第5章 全球OIC治療藥市場:藥物類別

  • 概要
  • 開發平台分析

第6章 全球OIC治療藥市場:處方類別

  • 處方藥
  • OTC藥

第7章 主要分析

  • 五力分析模型
  • 業者情勢
  • 機會矩陣

第8章 全球OIC治療藥市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第9章 企業簡介

  • IRONWOOD PHARMACEUTICALS INC
  • 第一三共
  • PFIZER
  • PROGENICS PHARMACEUTICALS INC
  • 鹽野義製藥
  • ALLERGAN PLC
  • NEKTAR THERAPEUTICS
  • PURDUE PHARMA L.P.
  • S.L.A. PHARMA AG
  • MUNDIPHARMA INTERNATIONAL LIMITED
  • 小野藥品工業
  • 武田藥品工業
  • THERAVANCE BIOPHARMA INC
  • VALEANT PHARMACEUTICALS INTERNATIONAL
  • COSMO PHARMACEUTICALS SA
  • DAEWOONG PHARMACEUTICAL CO., LTD.
  • C.B. FLEET COMPANY, INC.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 6725

KEY FINDINGS

Global Opioid Induced Constipation (OIC) drug market is estimated to grow at a CAGR of 4.88% during the forecast period of 2017 - 2025. The major drivers responsible for the market growth include the growing use of opioid, rising geriatric population, growing opioid prescription in North America and Europe, detection of safety threats and the easy availability of improved and effective OIC drugs. Some of the commonly prescribed opioids are Percocet, Vicodin, and codeine.

MARKET INSIGHTS

The global Opioid Induced Constipation (OIC) drug market segments include drug type and prescription type. The drug types are further classified into Methyl naltrexone Bromide, Naloxegol, and Lubiprostone. The prescription types are further classified into prescribed and over the counter. Of these, the Over the counter segment is dominating the market as a doctor's prescription is not required to buy the drugs which make its access much easier.

REGIONAL INSIGHTS

Geographically, the global Opioid Induced Constipation (OIC) is segmented into the following regions:

North America - U.S. & Canada

Asia Pacific - China, Japan, and RoAPAC

Europe - UK, Germany, and RoE

Rest of World - MENA and Latin America

Of these, the North American market is expected to dominate the global OIC drugs market during the forecast period on account of the fact that approximately 50% of the population is suffering from OIC. The countries in this region also have the most developed healthcare systems and medical devices industry in the world. The Federal agencies and private firms are equally supporting the market by providing access to the best medical facilities to the consumers. Growing life style oriented diseases, increase in healthcare spending and technological advancement in cardiology are the factors responsible for the growth of this market.

COMPETITIVE INSIGHTS

Product launch is the key strategy adopted by the various market players of global Opioid Induced Constipation (OIC) drug market.The AstraZeneca Pharmaceuticals's Movantik developed a partnership with Nektar Therapeutics in 2014 for the treatment of OIC. Another merger of Salix Pharmaceuticals and Progenics Pharmaceuticals developed Relistor drug that is expected to generate around $150 million by 2020. The other major market players include Takeda Pharmaceutical, Valeant Pharmaceuticals International, Abbott Laboratories and Sucampo AG

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY

4. MARKET OVERVIEW

  • 4.1. MARKET DEFINITION
  • 4.2. KEY MARKET INSIGHTS
  • 4.3. ATTRACTIVE INVESTMENT SCENARIO
  • 4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
  • 4.5. MARKET DRIVERS
    • 4.5.1. RISING USE OF OPIOID
    • 4.5.2. INCREASING GERIATRIC POPULATION
    • 4.5.3. INCREASING OPIOIDS PRESCRIPTION IN NORTH AMERICA AND EUROPE
    • 4.5.4. EASY AVAILABILITY OF IMPROVED AND EFFECTIVE OIC DRUGS
  • 4.6. RESTRAINTS
    • 4.6.1. RESEARCH ON PAIN AND NEXT GENERATION ANALGESICS
    • 4.6.2. SIDE EFFECTS OF OIC DRUGS
    • 4.6.3. UNAWARENESS AND IGNORANCE AMONG PATIENTS
  • 4.7. OPPORTUNITY
    • 4.7.1. RISING DEMAND FOR OIC DRUGS FROM APAC MARKET
    • 4.7.2. INCREASING USE OF OPIOIDS
  • 4.8. CHALLENGES
    • 4.8.1. LARGE NUMBER OF CONSIDERATIONS WHILE USING OPIOIDS

5. GLOBAL OIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)

  • 5.1. OVERVIEW
    • 5.1.1. METHYL NALTREXONE BROMIDE
    • 5.1.2. LUBIPROSTONE
    • 5.1.3. NALOXEGOL
  • 5.2. PIPELINE DRUG ANALYSIS: PHASE 3: NALDEMEDINE (YEAR OF LAUNCH TO 2022 $ MILLION)
  • 5.3. PIPELINE DRUG ANALYSIS: PHASE 2: ALVIMOPAN, DOLCANATIDE (QUALITATIVE INFORMATION)
  • 5.4. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH TO 2022 $ MILLION)

6. GLOBAL CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

  • 6.1. PRESCRIBED DRUGS
    • 6.1.1. BRANDED
    • 6.1.2. GENERIC
  • 6.2. OVER THE COUNTER DRUGS

7. KEY ANALYTICS

  • 7.1. PORTERS FIVE FORCE MODEL
    • 7.1.1. INTENSITY OF COMPETITIVE RIVALRY
    • 7.1.2. BARGAINING POWER OF SUPPLIERS
    • 7.1.3. BARGAINING POWER OF BUYERS
    • 7.1.4. THREAT OF SUBSTITUTE PRODUCTS
    • 7.1.5. THREAT OF NEW ENTRANTS
  • 7.2. VENDOR LANDSCAPE
  • 7.3. OPPORTUNITY MATRIX

8. GLOBAL OIC DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

  • 8.1. NORTH AMERICA
    • 8.1.1. US
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. UK
    • 8.2.2. GERMANY
    • 8.2.3. REST OF THE EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. CHINA
    • 8.3.2. JAPAN
    • 8.3.3. REST OF ASIA PACIFIC
  • 8.4. REST OF THE WORLD
    • 8.4.1. MIDDLE EAST AND AFRICA
    • 8.4.2. LATIN AMERICA
    • 8.4.3. REST OF THE ROW

9. COMPANY PROFILE

  • 9.1. IRONWOOD PHARMACEUTICALS INC
    • 9.1.1. OVERVIEW
    • 9.1.2. PRODUCT PORTFOLIO
    • 9.1.3. STRATEGIC MOVES
    • 9.1.4. SCOT ANALYSIS
  • 9.2. DAIICHI SANKYO CO LTD
    • 9.2.1. OVERVIEW
    • 9.2.2. PRODUCT PORTFOLIO
    • 9.2.3. STRATEGIC MOVES
    • 9.2.4. SCOT ANALYSIS
  • 9.3. PFIZER
    • 9.3.1. OVERVIEW
    • 9.3.2. PRODUCT PORTFOLIO
    • 9.3.3. STRATEGIC MOVES
    • 9.3.4. SCOT ANALYSIS
  • 9.4. PROGENICS PHARMACEUTICALS INC
    • 9.4.1. OVERVIEW
    • 9.4.2. STRATEGIC MOVES
    • 9.4.3. SCOT ANALYSIS
  • 9.5. SHIONOGI & CO., LTD.
    • 9.5.1. OVERVIEW
    • 9.5.2. PRODUCT PORTFOLIO
    • 9.5.3. STRATEGIC MOVES
    • 9.5.4. SCOT ANALYSIS
  • 9.6. ALLERGAN PLC
    • 9.6.1. OVERVIEW
    • 9.6.2. PRODUCT PORTFOLIO
    • 9.6.3. STRATEGIC MOVES
    • 9.6.4. SCOT ANALYSIS
  • 9.7. NEKTAR THERAPEUTICS
    • 9.7.1. OVERVIEW
    • 9.7.2. PRODUCT PORTFOLIO
    • 9.7.3. STRATEGIC MOVES
    • 9.7.4. SCOT ANALYSIS
  • 9.8. PURDUE PHARMA L.P.
    • 9.8.1. OVERVIEW
    • 9.8.2. PRODUCT PORTFOLIO
    • 9.8.3. STRATEGIC MOVES
    • 9.8.4. SCOT ANALYSIS
  • 9.9. S.L.A. PHARMA AG
    • 9.9.1. OVERVIEW
    • 9.9.2. PRODUCT PORTFOLIO
    • 9.9.3. SCOT ANALYSIS
  • 9.10. MUNDIPHARMA INTERNATIONAL LIMITED
    • 9.10.1. OVERVIEW
    • 9.10.2. PRODUCT PORTFOLIO
    • 9.10.3. STRATEGIC MOVES
    • 9.10.4. SCOT ANALYSIS
  • 9.11. ONO PHARMACEUTICAL CO., LTD.
    • 9.11.1. OVERVIEW
    • 9.11.2. PRODUCT PORTFOLIO
    • 9.11.3. STRATEGIC MOVES
    • 9.11.4. SCOT ANALYSIS
  • 9.12. TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 9.12.1. OVERVIEW
    • 9.12.2. PRODUCT PORTFOLIO
    • 9.12.3. STRATEGIC MOVES
    • 9.12.4. SCOT ANALYSIS
  • 9.13. THERAVANCE BIOPHARMA INC
    • 9.13.1. OVERVIEW
    • 9.13.2. PRODUCT PORTFOLIO
    • 9.13.3. STRATEGIC MOVES
    • 9.13.4. SCOT ANALYSIS
  • 9.14. VALEANT PHARMACEUTICALS INTERNATIONAL
    • 9.14.1. OVERVIEW
    • 9.14.2. PRODUCT PORTFOLIO
    • 9.14.3. STRATEGIC MOVES
    • 9.14.4. SCOT ANALYSIS
  • 9.15. COSMO PHARMACEUTICALS SA
    • 9.15.1. OVERVIEW
    • 9.15.2. PRODUCT PORTFOLIO
    • 9.15.3. STRATEGIC MOVES
    • 9.15.4. SCOT ANALYSIS
  • 9.16. DAEWOONG PHARMACEUTICAL CO., LTD.
    • 9.16.1. OVERVIEW
    • 9.16.2. PRODUCT PORTFOLIO
    • 9.16.3. STRATEGIC MOVES
    • 9.16.4. SCOT ANALYSIS
  • 9.17. C.B. FLEET COMPANY, INC.
    • 9.17.1. OVERVIEW
    • 9.17.2. PRODUCT PORTFOLIO
    • 9.17.3. STRATEGIC MOVES
    • 9.17.4. SCOT ANALYSIS

LIST OF TABLES

  • TABLE 1 GLOBAL OIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 2 PHARMACOLOGICAL APPROACHES TO TREAT OPIOID INDUCED CONSTIPATION
  • TABLE 3 LAXATIVES USED FOR OPIOID INDUCED CONSTIPATION
  • TABLE 4 SIDE EFFECTS OF USING LAXATIVES
  • TABLE 5 PATIENTS UNFIT FOR INTAKE OF OPIOIDS
  • TABLE 6 GLOBAL OIC DRUG MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
  • TABLE 7 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
  • TABLE 8 GLOBAL METHYL NALTREXONE BROMIDE OIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($MILLION)
  • TABLE 9 PRODUCT PROFILE (LUBIPROSTONE)
  • TABLE 10 GLOBAL LUBIPROSTONE OIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($MILLION)
  • TABLE 11 PRODUCT PROFILE (NALOXEGOL)
  • TABLE 12 GLOBAL NALOXEGOL OIC DRUG MARKET BY GEOGRAPHY 2017-2025 ($MILLION)
  • TABLE 13 PIPELINE PRODUCT PROFILE (NALDEMEDINE)
  • TABLE 14 PIPELINE PRODUCT PROFILE (ALVIMOPAN, DOLCANATIDE)
  • TABLE 15 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
  • TABLE 16 GLOBAL OIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
  • TABLE 17 PRODUCT PROFILE (LUBIPROSTONE)
  • TABLE 18 GLOBAL PRESCRIBED OIC DRUGS MARKET 2017-2025($ MILLION)
  • TABLE 19 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
  • TABLE 20 PRODUCT PROFILE (METAMUCIL)
  • TABLE 21 PRODUCT PROFILE (BISACODYL)
  • TABLE 22 GLOBAL OVER THE COUNTER OIC DRUG BY GEOGRAPHY 2017-2025($ MILLION)
  • TABLE 23 GLOBAL OIC DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
  • TABLE 24 NORTH AMERICA OIC DRUGS MARKET BY COUNTRY, 2017-2025($ MILLION)
  • TABLE 25 EUROPE OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
  • TABLE 26 ASIA PACIFIC OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
  • TABLE 27 REST OF WORLD OIC DRUG MARKET 2017-2025 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL OIC DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 2 GLOBAL OIC DRUG MARKET BY DRUG TYPE 2016 AND 2025 (%)
  • FIGURE 3 GLOBAL OIC DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
  • FIGURE 4 INCREASING NUMBER OF OPIOID PRESCRIPTION ($ MILLION)
  • FIGURE 5 REASONS FOR THE GROWTH OF OPIOID MARKET.
  • FIGURE 6 THERAPEUTIC OPIOID USE IN US (G/100,000 POPULATION)
  • FIGURE 7 COMMON SIDE EFFECTS OF MOVANTIK
  • FIGURE 8 MAJOR USAGE OF OPIOIDS
  • FIGURE 9 CONSIDERATIONS TAKEN WHILE THE OPIOID USAGE
  • FIGURE 10 GLOBAL METHYL NALTREXONE BROMIDE OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 11 GLOBAL LUBIPROSTONE OIC DRUG MARKET 2017-2025 ($MILLION)
  • FIGURE 12 GLOBAL NALOXEGOL OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 13 GLOBAL PRESCRIBED OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 14 GLOBAL PRESCRIBED BRANDED OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 15 GLOBAL PRESCRIBED GENERIC OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 16 GLOBAL OVER THE COUNTER OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 17 NORTH AMERICA OIC DRUGS MARKET 2017-2025 ($ MILLION)
  • FIGURE 18 US OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 19 CANADA OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 20 NUMBER OF PRESCRIPTIONS DISPENSED FOR OPIOIDS
  • FIGURE 21 EUROPE OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 22 UK OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 23 GERMANY OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 24 REST OF EUROPE OIC DRUG MARKET 2017-2025($ MILLION)
  • FIGURE 25 ASIA PACIFIC OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 26 CHINA OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 27 PHARMACEUTICALS MARKET SALES ACROSS THE GLOBE (%)
  • FIGURE 28 JAPAN OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 29 REST OF APAC OIC DRUG MARKET 2017-2025 ($ MILLION)
  • FIGURE 30 MIDDLE EAST AND AFRICA OIC DRUG MARKET 2017-2025($ MILLION)
  • FIGURE 31 LATIN AMERICA OIC DRUG MARKET 2017-2025($ MILLION)
  • FIGURE 32 REST OF ROW OIC DRUG MARKET 2017-2025($ MILLION)
Back to Top